Recombinant Human Eukaryotic Translation Initiation Factor 4 Gamma 1 (EIF4G1) Protein (His-B2M-JD&Myc)

Name: Recombinant Human Eukaryotic Translation Initiation Factor 4 Gamma 1 (EIF4G1) Protein (His-B2M-JD&Myc)
Brand: Beta LifeScience
SKU: BLC-02165P
Availability: InStock

Greater than 85% as determined by SDS-PAGE.

Collections: Fc receptors, Other recombinant proteins, Recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Eukaryotic Translation Initiation Factor 4 Gamma 1 (EIF4G1) Protein (His-B2M-JD&Myc) is produced by our E.coli expression system. This is a protein fragment.
Purity	Greater than 85% as determined by SDS-PAGE.
Uniprotkb	Q04637
Target Symbol	EIF4G1
Synonyms	DKFZp686A1451; eIF 4 gamma 1; eIF 4G 1; eIF 4G1; eIF-4-gamma 1; eIF-4G 1; eIF-4G1; EIF4 gamma; EIF4F; EIF4G; EIF4G1; EIF4GI; Eukaryotic translation initiation factor 4 gamma 1; IF4G1_HUMAN; p220
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	N-10His-B2M-JD&C-Myc
Target Protein Sequence	IEEYLHLNDMKEAVQCVQELASPSLLFIFVRHGVESTLERSAIAREHMGQLLHQLLCAGHLSTAQYYQGLYEILELAEDMEIDIPHVWLYLAELVTPILQEGGVPMGELFREITKPLRPLGKAASLLLEILGLLCKSMGPKKVGTLWREAGLSWKEFLPEGQDIGAFVAEQKVEYTLGEESEAPGQRALPSEELNRQLEKLLKEGSSNQRVFDWIEANLSEQQIVSNTLVRALMTAVCYSAIIFETPLRVDVAVLKARAKLLQKYLCDEQKELQALYALQALVVTLEQPPNLLRMFFDALYDEDVVKEDAFYSWESSKDPAEQQGKGVALKSVTAFFKWLREAEEESDHN
Expression Range	1250-1599aa
Protein Length	Partial
Mol. Weight	46.6 kDa
Research Area	Epigenetics And Nuclear Signaling
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Component of the protein complex eIF4F, which is involved in the recognition of the mRNA cap, ATP-dependent unwinding of 5'-terminal secondary structure and recruitment of mRNA to the ribosome. As a member of the eIF4F complex, required for endoplasmic reticulum stress-induced ATF4 mRNA translation.
Subcellular Location	Cytoplasm, Stress granule.
Protein Families	Eukaryotic initiation factor 4G family
Database References	HGNC: 3296 OMIM: 600495 KEGG: hsa:1981 STRING: 9606.ENSP00000338020 UniGene: Hs.433750
Associated Diseases	Parkinson disease 18 (PARK18)

Gene Functions References

The polymorphism of the rs200221361 may have no association with the occurrence of Parkinson disease in Uygur and Han people of Xinjiang. PMID: 29718834
Epstein-Barr Virus protein EB2 first is recruited to the mRNA cap structure in the nucleus and then interacts with the proteins eIF4G and PABP to enhance the initiation step of translation. PMID: 29142127
EIF4G1 overexpression is associated with non-small cell lung cancers. PMID: 27003362
High EIF4G expression is associated with malignant peripheral nerve sheath tumors and vestibular schwannomas. PMID: 26951381
The study indicates that the EIF4G1 mutation is rare in Taiwan, which is consistent with other reports from Asia. Ethnicity could have a great influence on EIF4G1 in Parkinson's disease. PMID: 26490695
the IRES of encephalomyocarditis virus (EMCV) interacts with the HEAT-1 domain of eukaryotic initiation factor 4G (eIF4G). PMID: 27525590
EIF4G1 mutations are not related to Parkinson's disease PMID: 26022768
VPS35 D620N and EIF4G1 R1205H mutations are not a common cause of Parkinson disease in the Greek population. PMID: 26300542
EIF4GI shares this activity and also interacts with eIF1. PMID: 25738462
EIF4G1 is neither a strong nor a common risk factor for Parkinson's disease: evidence from large European cohorts. PMID: 25368108
This study therefore implicates c-Myc as a potential regulator of the cancer-promoting effects of equol via up-regulation of eIF4GI and selective initiation of translation on mRNAs that utilize non-canonical initiation, including certain oncogenes PMID: 25593313
Knockdown of eIF4GI was deleterious to myeloma cells phenotype and expression of specific molecular targets (SMAD5/ERalpha/HIF1alpha/c-Myc). PMID: 24815186
Its mutation is not a common cause of familial Parkinson's disease. PMID: 24854799
in a generic cell model, new insights into the mechanisms whereby the FSH receptor controls translation have been gained. Rapamycin-sensitive eIF4G phosphorylation at the 5' cap may be a surrogate for the classical exchange between eIF4G and 4E-BP1. PMID: 24711644
The results of this study did not identify novel or previously reported pathogenic mutations (including the p.A502V and p.R1205H mutants) within EIF4G1 in the Japanese population. PMID: 24704100
Data suggest that, in eIF4G/eif4A complex, eIF4G1 exhibits low-affinity ATP binding site in proximity of ATP-binding cleft of eif4A enhancing ATP binding; additional enhancement of eIF4G/eif4A binding is observed in crowded/intracellular environment. PMID: 25255371
study revealed that the EIF4G1 R1205H and VPS35 D620N mutations were absent in 418 Parkinsoin Disease patients of various South African ethnic groups PMID: 24080171
Report EIF4G binding within the IRES domain V of the coxsackie virus B3 mutant strain. PMID: 24063684
Its mutation causes Parkinson's disease in Indian population. PMID: 23726718
eukaryotic initiation factor 4G (eIF4G) protein binds to eIF3c, -d, and -e to promote mRNA recruitment to the ribosome. PMID: 24092755
EIF4G1 mutations do not appear to play a role in patients with Parkinson disease from southwest China. PMID: 23261770
The eIF4E-binding site in eukaryotic initiation factor 4G (eIF4G) functions as an autoinhibitory domain to modulate its ability to stimulate eIF4A helicase activity. PMID: 23901100
The data of this study indicated that in an ethnic Chinese population, the pathogenic mutation p.R1205H in EIF4G1 is not common and that EIF4G1 exonic variants rs2178403 and rs13319149 are not associated with parkinson disease. PMID: 23617574
The results suggest that in some patients variants in EIF4G1 can be associated with pathology that has a high likelihood of association with clinical features of dementia with Lewy bodies. PMID: 23124435
the EIF4G1 p.Ala502Val and p.Arg1205His variants are a rare cause of PD, at least in Chinese population. PMID: 23562511
In agreement with recent reports we conclude that convincing evidence establishes EIF4G1 mutations as a rare cause of Parkinson's disease PMID: 23490116
eIF4GI participates in the miRNA-mediated post-transcriptional gene silencing by promoting the association of Ago2 with the cap-binding complex. PMID: 23409027
EIF4G1 is an uncommon cause of PD in our Asian cohort. PMID: 23092605
There is no evidence for an overall contribution of genetic variability in EIF4G1 (or VPS35) to Parkinson disease development in this large family. PMID: 23408866
Results provide a mechanistic link between intracellular signal transduction and dynamic initiation complex formation coordinated by flexible eIF4G structure. PMID: 23263986
Data show that eIF4G interacts with the RRM2 domain of polyadenylate-binding protein-1 (PABP). PMID: 23041282
Increased expression of eIF4G1 therefore promotes specialized translation of survival, growth arrest, and DDR mRNAs that are important in cell survival and DNA repair following genotoxic DNA damage. PMID: 23112151
EIF4G1 cDNAs, encoding different isoforms which arise through selection of alternative initiation codons, rescued translation from siRNA interference to different extents PMID: 22909319
analysis of variants of eukaryotic translation initiation factor 4G1 in sporadic Parkinson\'s disease PMID: 22707335
These data do not support the pathogenicity of several EIF4G1 variants in PD, at least in the French population. PMID: 22658323
linkage analysis, mutations in EIF4G1 were implicated as a cause of Parkinson disease and mutations in SLC20A2 as a cause of familial idiopathic basal ganglia calcification. PMID: 22772876
Found that either EIF4G1 variants are an extremely rare cause of familial Parkinson's Disease in Caucasian cohorts, or that A502V is in fact a rare benign variant not involved in Parkinson's Disease aetiology PMID: 22561553
This finding demonstrates that viruses can increase host translation initiation factor concentration to foster their replication and defines a unique mechanism whereby control of PABP abundance regulates eIF4F assembly. PMID: 22431630
The ssDNA-binding protein of Vaccinia virus, I3 interacts and co-localizes with the eIF4F scaffold protein, eIF4G inInfected cells. PMID: 22280895
EIF4G1 mutations implicate mRNA translation initiation in familial parkinsonism. PMID: 21907011
Data show that PKCalpha activation elicits a cascade of orchestrated phosphorylation events that may modulate eIF4G1 structure and control interaction with the eIF4E kinase, Mnk1. PMID: 21576361
EIF4G1 can serve as a biomarker for the prognosis of nasopharyngeal carcinoma patients. PMID: 20398343
HIV- 1 protease inhibits Cap- and poly(A)-dependent translation upon eIF4GI and PABP cleavage PMID: 19956697
findings assign NAD(P)H quinone-oxydoreductase 1 an original role in the regulation of mRNA translation via the control of eIF4GI stability by the proteasome. PMID: 20028737
mass spectrometric analysis of N terminus reveals novel isoforms PMID: 11821405
demonstrate that the expression of the amino-terminal one-third of eIF4G, which interacts with eIF4E and PABP, in Xenopus oocyte inhibits translation and progesterone-induced maturation PMID: 11866104
data suggest that expression of the eIF4GI isoforms is partly controlled by a complex translation strategy involving both cap-dependent and cap-independent mechanisms PMID: 12052860
X-ray structure of rotavirus NSP3-C bound to the 30 residue fragment of eIF4G that is also recognized by poly(A) binding protein (PABP) PMID: 12086624
proteolytic activity of HIV-1 protease on eIF4GI and eIF4GII and its implications for the translation of mRNAs PMID: 12505164
Overexpression of EIF4G1 causes aberrant cell morphology and results in disruption of the localization of F-actin and the organization of microtubules. PMID: 12581158

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.